CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

뉴스 본문을 불러오고 있어요.

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026 | 웨이프 WAPE

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

기사 요약

관련 종목

댓글 —